Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,279
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,975.70 | 35.30 | 0.39% |
| CAC 40 | 7,868.05 | 88.65 | -1.11% |
| DAX 40 | 25,319.77 | 302.84 | -1.18% |
| Dow JONES (US) | 52,053.73 | 51.32 | 0.10% |
| FTSE 100 | 10,764.69 | 117.21 | -1.08% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,484.87 | 344.83 | 1.32% |
| Nikkei 225 | 64,916.70 | 407.59 | -0.62% |
| NZX 50 Index | 13,652.07 | 101.66 | -0.74% |
| S&P 500 | 7,706.37 | 46.93 | 0.61% |
| S&P/ASX 200 | 8,845.70 | 39.00 | 0.44% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |